Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
On November 12, 2021, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate overview at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On November 12, 2021, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate overview at the Stifel 2021 Virtual Healthcare Conference from November 15-17, 2021. The presentation is scheduled for November 17 at 2:00 PM ET and will be accessible via webcast on the company’s website. Immunovant is focused on developing IMVT-1401 (batoclimab), a monoclonal antibody aimed at treating autoimmune diseases mediated by IgG antibodies.
Details
News Market Reaction – IMVT
The recorded move for IMVT in the trading session of this news was +0.94%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the Stifel 2021 Virtual Healthcare Conference, taking place November 15-17, 2021.
Stifel 2021 Virtual Healthcare Conference Presentation
| Date: | Wednesday, November 17th, 2021 |
| Time: | 2:00pm Eastern Time |
| Webcast: | The presentation will be available via webcast and can be accessed at the Investor Relations section of the Company’s website, located at www.immunovant.com |
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing IMVT-1401 (batoclimab), a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.
Contact:
Tom Dorney, MS, MBA
Director, Investor Relations & Strategy
Immunovant, Inc.
info@immunovant.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.